Lanzhou Foci Pharmaceutical (002644) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

CN Stock MarketDetailed Quotes

002644 Lanzhou Foci Pharmaceutical

Watchlist

8.18
+0.04+0.49%

Not Open Dec 20 15:00 CST

4.18BMarket Cap90.89P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

A Look At The Intrinsic Value Of LanZhou Foci Pharmaceutical Co.,Ltd. (SZSE:002644)
Simply Wall StDec 13 19:31 ET
Buddha\'s Pharmaceutical: Report for the third quarter of 2024
SZSIOct 25 12:00 ET · Announcements
Earnings Troubles May Signal Larger Issues for LanZhou Foci PharmaceuticalLtd (SZSE:002644) Shareholders
Simply Wall StSep 2 02:53 ET
Buddha\'s Pharmaceutical: 2024 Semi-Annual Report Summary
SZSIAug 26 12:00 ET · Announcements
Buddha Tzu Pharmaceuticals: Semi-Annual Report 2024
SZSIAug 26 12:00 ET · Announcements
LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Simply Wall StAug 6 18:16 ET

Comments

Moomoo AI

Feb 1 18:24

Despite limited growth and weaker momentum, LanZhou Foci PharmaceuticalLtd's high P/E ratio indicates investors' hope for a business turnaround. However, if P/E aligns with recent growth rates, shareholders may face disappointment. Weak earnings and slower growth could risk investments and potential investors may pay an excessive premium.

LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 28% Share Price Plunge Could Signal Some Risk

Moomoo AI

Jan 9 19:31

The company's strong EPS growth and reasonable CEO compensation suggest good governance and alignment with shareholder interests. The company's financial performance makes it worth watching for growth investors.